Prostate Cancer

Dear Dr. Roach: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. — M.D. Dear M.D.: I always appreciate hearing differing opinions from my own, and here

Dear Dr. Roach: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. A: I always appreciate hearing differing opinions from my own, and here is wh

Prostate cancer  is the most common type of cancer to be diagnosed in men, in the UK. The diseases affects the prostate - a small gland that’s found in the pelvis in men. It’s not always easy to know if you’re at risk of prostate cancer, as the symptoms tend to develop very slowly over a long period of time. You could be at risk of prostate cancer if you suddenly find yourself needing to pass urine more often than normal, it’s been revealed. Recent urination could be one of the earliest warning signs of prostate cancer, said medical website Cancer.Net. It may be caused by the tumour growing large enough to put pressure on the urethra - the tube that carries urine from the bladder. This pressure could also lead to hesitancy when starting to pass urine, or having a particularly weak flow of urine. “Often, early-stage prostate cancer has no symptoms or signs,” it said. “It is usually found through a PSA test or DRE, a process called screening. “When prostate cancer does cause sym

February 27, 2019 Share this content: New tool promises to help patients decide whether radical prostatectomy or radiation therapy is their best treatment option. Researchers at the University of Michigan in Ann Arbor have proposed an online calculator to aid patients with localized prostate cancer (PCa) in deciding whether surgery or radiation therapy is their best treatment option, a question that randomized trials have not fully addressed. “Helping guide men with localized prostate cancer through their initial treatment decision is one of the most important things we do as prostate cancer specialists, study investigator Todd M. Morgan, MD, associate professor of urologic oncology, told Renal & Urology News . “Despite the number of men who have to face these decisions each year, we have very little prospective, randomized data to help steer our recommendations.” Continue Reading Below Clinicians now must rely on reams of retrospective, observational data, which are of

DEAR DR. ROACH: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. — M.D. ANSWER: I always appreciate hearing differing opinions from my own, and here is

Typically, active surveillance involves prostate-specific antigen (PSA) tests every three to six months, digital rectal examination every six months, mpMRI scans, and biopsies at 12 months and three years. If the cancer shows sign of faster or more aggressive growth, a patient can start treatment or undergo surgery. https://ift.tt/2ElWNoD

February 27, 2019 Share this content: New tool promises to help patients decide whether radical prostatectomy or radiation therapy is their best treatment option. Researchers at the University of Michigan in Ann Arbor have proposed an online calculator to aid patients with localized prostate cancer (PCa) in deciding whether surgery or radiation therapy is their best treatment option, a question that randomized trials have not fully addressed. “Helping guide men with localized prostate cancer through their initial treatment decision is one of the most important things we do as prostate cancer specialists, study investigator Todd M. Morgan, MD, associate professor of urologic oncology, told Renal & Urology News . “Despite the number of men who have to face these decisions each year, we have very little prospective, randomized data to help steer our recommendations.” Continue Reading Below Clinicians now must rely on reams of retrospective, observational data, which are of

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s  Privacy Policy  and  Terms & Conditions . https://ift.tt/2NzRSVh

DEAR DR. ROACH: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. — M.D. ANSWER: I always appreciate hearing differing opinions from my own, and here is

Affecting approximately 38,000 men annually in the United States, metastatic hormone-sensitive prostate cancer (mHSPC) is a deadly form of cancer . Hormone, or castration, sensitivity refers to the fact that the disease still responds to medical or surgical treatment to lower testosterone levels.   The combination of enzalutamide (Xtandi, Astellas Pharma and Pfizer), an androgen receptor inhibitor, and androgen deprivation therapy (ADT) has found to improve radiographic progression-free survival in men with mHSPC.   Held at sites in the United States, Canada, Europe, South America and the Asia-Pacific region, the Phase 3 ARCHES trial was a randomized, double-blind, placebo-controlled, and international study that enrolled 1150 mHSPC patients. Patients were randomized to either receive a daily dose of 160-mg enzalutamide or placebo, and continued on a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist or had a history of bilateral orchiectomy, according to the press

DUBLIN--( BUSINESS WIRE )--The "Metastatic Prostate Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Metastatic Prostate Cancer - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Prostate Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental Stages: Clinical Non-clinical Inactive: Discontinued and/or Dormant Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, desi

Urology-related robotic surgery is a huge benefit to patients who previously would have had to undergo open surgery with its long incisions and long hospital stays, said Dr. Hoyt B. Doak IV of CarolinaEast Urology in New Bern. “For us that’s a really big deal, to be able to avoid a big open incision,” said Doak, who has been doing robotic surgeries for seven years, with five of those years at CarolinaEast Medical Center. While surgeons in other specialties could be doing some surgeries robotically, laparoscopically or open, those in urology essentially have only two choices – robotic or open, he said. “The cases that we do in urology are cases that are mostly just too technically difficult to be done laparoscopically,” Doak said. “They require sewing and fairly complex reconstruction that requires suturing. It is very difficult laparoscopically unless you’re a highly experienced laparoscopic surgeon that doesn’t really do anything else.” In urology, robotic surgery is compared to o

Prostate cancer  is the most common type of cancer to be diagnosed in men, in the UK. The diseases affects the prostate - a small gland that’s found in the pelvis in men. It’s not always easy to know if you’re at risk of prostate cancer, as the symptoms tend to develop very slowly over a long period of time. You could be at risk of prostate cancer if you suddenly find yourself needing to pass urine more often than normal, it’s been revealed. Recent urination could be one of the earliest warning signs of prostate cancer, said medical website Cancer.Net. It may be caused by the tumour growing large enough to put pressure on the urethra - the tube that carries urine from the bladder. This pressure could also lead to hesitancy when starting to pass urine, or having a particularly weak flow of urine. “Often, early-stage prostate cancer has no symptoms or signs,” it said. “It is usually found through a PSA test or DRE, a process called screening. “When prostate cancer does cause sym

Cancer is a condition where cells in the body grow and reproduce uncontrollably. These cancerous cells can then invade and destroy surrounding healthy tissue and organs and spread to other areas of the body. More than one in three people will develop some form of cancer during their lifetime, according to the NHS, but currently there is no cure. This makes recognising the symptoms of cancer very important to significantly improve your chances of survival. One of the most common types of cancer in the UK is prostate cancer , which just effects men. The prostate is a gland in the male body that adds part of the fluid to semen. Because of where the prostate is positioned in the body, many of the symptoms effect urination. Here are six signs to watch out for when you urinate which could signal prostate cancer, according to Cancer Research UK. Passing urine more often Also referred to as frequent urination, prostate cancer may give you the urge to need to empty your bladder more

Q: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. Receive today's headlines in your inbox with our daily news email SUBSCRIBE TODAY

[unable to retrieve full-text content] HSD3B1 Variants Linked With Outcomes of Prostate Cancer Treatments    Cancer Network HSD3B1 genotype may be a predictive biomarker for the use of androgen deprivation therapy (ADT) or abiraterone in Japanese men with prostate cancer, ... https://ift.tt/2Xsc8gf

Dear Dr. Roach: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. A: I always appreciate hearing differing opinions from my own, and here is wh

CHARLOTTE, N.C., Feb. 25, 2019 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, has partnered with Urology Associates, P.C., the largest private urology practice in the Nashville metro area with over 40 healthcare providers. Physicians at Urology Associates, P.C. are committed to being at the forefront of the latest technologies, surgical techniques and advanced treatment options. They have been offering HIFU, high intensity focused ultrasound, to their patients since 2016 but have recently partnered with HIFU Prostate Services to help expand their current HIFU program and provide support for patients seeking HIFU as a treatment for localized prostate cancer. Urology Associates is a large and growing practice. With over 30 board certified urologists and 12 advanced practice providers, providing male and female urologic care in over 20 locations, they pride themselves on treating every patient with exp

Increase in cost of inpatient stay for patients with prostate cancer is likely due to advances in multi-modality treatment, according to a study presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (February 14-16, 2019; San Francisco, CA). Given the complexity of health care costs, more variables should be considered to rationalize health care spending, the study also contends. While efforts from the Centers for Medicare and Medicaid Services (ie, close monitoring of length of inpatient stay) are in place to curtail costs of care for patients with cancer, the economic burden of novel treatments is becoming increasingly apparent. In prostate cancer, SEER analysis shows a 5-year overall survival of 98.2% and incidence of 179.1 in 2000 compared with 97.8% in 2015 per 100,000, respectively. However, this result is accompanied by increasing health care costs. Dhruv Bansal, MD, and John Wong, MD, both with Loma Linda University Medical Center (CA)

Dear Dr. Roach: I read your recent column on prostate cancer treatments, and I must disagree on the differences between IMRT and proton radiation therapy. IMRT or X-rays can cause secondary aggressive cancers of the bowels or bladder. I know of an individual who died from this type of cancer after IMRT. Proton radiation therapy does not cause secondary cancers because of the way protons work. Secondary cancers due to IMRT occur in about 8 percent of patients. This may be acceptable odds for radiation oncologists, but not to patients who develop them. Also, many doctors own the IMRT machinery and will send patients there for financial reward, which is what happened with my former urologist. When I found this out, I terminated my relationship with him. I hope this explains why I consider any treatment other than proton radiation therapy for prostate cancer to be archaic medicine and not to be used. A: I always appreciate hearing differing opinions from my own, and here is wh

GOLDEN VALLEY, Minn. — “We're ready to go," says the radiation tech. Radiation treatment number 18 for me at Minnesota Oncology in Maplewood. After much thought, I chose this option, radiation combined with the drug, Lupron, over robotic surgery and other treatments for prostate cancer.  Lupron turns off testosterone in men, which basically kills the cancer. But radiation is used to make sure it's gone both inside and outside the prostate. For me, 26 radiation treatments in all.  Having been through cancer before, radiation is a relative breeze compared to chemo - but all treatments have side effects and prostate cancer treatment has its fair share. And most men actually choose treatment based on the side effects they can live with. Watch Randy's full story - and his warnings for other men - tonight at 10. https://ift.tt/2tD6ZEb

Please enable Javascript to watch this video ST. LOUIS - A landmark study in the fight against prostate cancer is producing promising results. Scientists at Washington University and Siteman Cancer Center are conducting the research which is giving new hope to patients diagnosed with the deadly disease. "Two years ago, I was diagnosed with prostate cancer," said 67-year-old Bill Petersen, a loving husband, father, and grandfather. "I had no symptoms at all." The cancer which spread to Petersen's bladder and bones was discovered during a routine doctor visit.  "They did an annual chemistry test and the PSA level instead of being below four which is normal it was nine," said Petersen.  Petersen's prostate-specific antigen or PSA rose to an alarming 46 within two months.  "The way it was rising, I wasn't sure I would be around." Taken aback by the devastating news, Petersen relied on his faith and his family to move forward.  &

Increase in cost of inpatient stay for patients with prostate cancer is likely due to advances in multi-modality treatment, according to a study presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (February 14-16, 2019; San Francisco, CA). Given the complexity of health care costs, more variables should be considered to rationalize health care spending, the study also contends. While efforts from the Centers for Medicare and Medicaid Services (ie, close monitoring of length of inpatient stay) are in place to curtail costs of care for patients with cancer, the economic burden of novel treatments is becoming increasingly apparent. In prostate cancer, SEER analysis shows a 5-year overall survival of 98.2% and incidence of 179.1 in 2000 compared with 97.8% in 2015 per 100,000, respectively. However, this result is accompanied by increasing health care costs. Dhruv Bansal, MD, and John Wong, MD, both with Loma Linda University Medical Center (CA)

[unable to retrieve full-text content] Updated Trial for PSMA-Targeted Therapy in Metastatic Prostate Cancer Excites    Cancer Network The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium. https://ift.tt/2EqPhKt

Please enable Javascript to watch this video ST. LOUIS - A landmark study in the fight against prostate cancer is producing promising results. Scientists at Washington University and Siteman Cancer Center are conducting the research which is giving new hope to patients diagnosed with the deadly disease. "Two years ago, I was diagnosed with prostate cancer," said 67-year-old Bill Petersen, a loving husband, father, and grandfather. "I had no symptoms at all." The cancer which spread to Petersen's bladder and bones was discovered during a routine doctor visit.  "They did an annual chemistry test and the PSA level instead of being below four which is normal it was nine," said Petersen.  Petersen's prostate-specific antigen or PSA rose to an alarming 46 within two months.  "The way it was rising, I wasn't sure I would be around." Taken aback by the devastating news, Petersen relied on his faith and his family to move forward.  &

To describe a technical modifi cation for robotic-assisted simple prostatectomy (RASP) using three-steps reconstructive technique to achieve a 360 trigonization of the bladder mucosa. Through fi ve-trocars transperitoneal access, we perform a longitudinal incision of the bladder wall and prostate capsule. Our technique of RASP is very similar to the standard operative technique described during laparoscopic and robotic removal of adenoma, however, for reconstruction, we propose the Tunnel-Shaped Trigonization (TST). The fi rst step is the advancement of a bladder mucosa fl ap until the posterior part of the prostatic urethra. The second step, a running suture between the advanced mucosa and the prostatic capsule is done bilaterally. At this point, the prostate capsule should be totally isolated from the rest of the urinary tract. Finally, the third step is closing both sides of the capsule and bladder mucosa anteriorly identical to a tunnel conformation. Hiding the prostatic capsule op

Xiaonan Zheng, 1, * Shi Qiu, 1,2, * Xinyang Liao, 1 Xin Han, 3 Kun Jin, 1 Lu Yang, 1 Qiang Wei 1 1 Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2 Center of Biomedical Big Data, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3 West China Medical School, Sichuan University, Chengdu, Sichuan, People’s Republic of China *These authors contributed equally to this work Objective: To evaluate the association between metabolic syndrome (MetS) and the accumulation of its components with prostate cancer (PCa). Patients and methods: Patients undergoing radical prostatectomy were retrospectively included. Patients were grouped by low risk and intermediate-high risk according to International Society of Urological Pathology grade. Multivariable logistic regression and Cox hazard regression model were utilized to assess the association of MetS with overall surviva

By Marilynn Larkin NEW YORK (Reuters Health) - Hypofractionated radiotherapy (HRT) should be a new practice standard for men with low-risk prostate cancer, based on a secondary analysis of a phase III trial. "The NRG Oncology Group previously demonstrated that men with low-risk prostate cancer had similar 5-year disease-free survival of about 85% when treated with either conventional radiotherapy (CRT) of 73.8 Gy in 41 fractions over 8.2 weeks, or with HRT of 70 Gy in 28 fractions over 5.6 weeks," Dr. Deborah Bruner of Emory University in Atlanta told Reuters Health by email. "However, late physician-reported side effects of mild bowel and bladder symptoms were increased in patients treated with HRT and raised questions whether the HRT arm is acceptable to patients," she noted. "The current study asked patients directly about their bowel, bladder, sexual function, anxiety, depression and general quality of life using valid patient-reported questionnaires,&q

MDxHealth has developed the most comprehensive solution for diagnosing prostate cancer, shifting treatment from a generic approach to a more personalised method. Across Europe and around the globe, innovators and leaders in healthcare are shifting from a one-size-fits-all mentality to a personalised, patient-centric approach, known as precision medicine, focused on improving patient outcomes, eliminating unnecessary invasive procedures and reducing healthcare costs by utilising the latest advanced molecular tests. Precision medicine offers non-invasive, powerful, accurate and often cost-effective tools to empower physicians to learn more about their patients’ specific conditions and needs, helping them make decisions faster with better outcomes. MDxHealth is a multinational molecular diagnostics company that is leading the precision medicine movement in urological oncology with its SelectMDx and ConfirmMDx for Prostate Cancer tests. The prostate cancer problem Prostate cancer is th